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ABSTRACT 
SUCNR1 (or GPR91) belongs to the family of G protein-coupled receptors (GPCR), which represents the largest 
group of membrane proteins in human genome. The majority of marketed drugs targets GPCRs, directly or 
indirectly. SUCNR1 has been classified as an orphan receptor until a landmark study paired it with succinate, a 
citric acid cycle intermediate. 
According to the current paradigm, succinate triggers SUCNR1 signaling pathways to indicate local stress that 
may affect cellular metabolism. SUCNR1 implication has been well documented in renin-induced hypertension, 
ischemia/reperfusion injury, inflammation and immune response, platelet aggregation and retinal angiogenesis. 
In addition, the SUCNR1-induced increase of blood pressure may contribute to diabetic nephropathy or cardiac 
hypertrophy. 
The understanding of SUCNR1 activation, signaling pathways and functions remains largely elusive, which calls 
for deeper investigations. SUCNR1 shows a high potential as an innovative drug target and is probably an 
important regulator of basic physiology. In order to achieve the full characterization of this receptor, more 
specific pharmacological tools such as small-molecules modulators will represent an important asset. In this 
review, we describe the structural features of SUCNR1, its current ligands and putative binding pocket. We give 
an exhaustive overview of the known and hypothetical signaling partners of the receptor in different in vitro and 
in vivo systems. The link between SUCNR1 intracellular pathways and its pathophysiological roles are also 
extensively discussed. 
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ABBREVIATIONS 
(GPCRs), G protein-coupled receptors family; (SUCNR.1), succinate receptor 1 ; (AA), amino acids; (7TM), 
seven transmembrane domains; (ECLs), extracellular loops; (ICLs), intracellular loops; (cAMP), cyclic 
adenosine monophosphate; (AC), adenylate cyclase; (GRKs), G protein-coupled receptor kinases; (CHO) cells, 
Chinese hamster ovary; (HEK293) cells, human embryonic kidney; (MDCK) cells, madin darby canin kidney; 
(iDC), immature dendritic cells; (PTX), pertussis toxin; (ERK1/2), extracellular signal-regulated kinases 1 and 2; 
(RGC), retina ganglion cells; (RAS), renin-angiotensin system; (JGA), juxtaglomerular apparatus; (MD), macula 
densa; (JG) cells, juxtaglomerular; (COX-2), cyclooxygenase 2; E2 (PGE2), prostaglandin; (PGI2), 
prostaglandin 12; (AA), arachidonic acid; (GENCs), juxtaglomerular endothelium cells; (NO), nitric oxide; 
(CH), cardiac hypertrophy; (CaMKIIδ), calcium/ calmodulin-dependent protein kinase IIδ; (HDAC5), histone 
deacetylase 5; (PKA), protein kinase A; (PLN), phospholamban; (RyR2), ryanodine receptor 2; (PDE), 
phosphodiesterase; (RVH), right ventricular hypertrophy; (LVH), left ventricle hypertrophy; (PI3K), 
phosphatidylinositol-4,5-bisphosphate 3-kinase; (Akt), protein kinase B; (WAT), white adipose tissue; (MS), 
metabolic syndrome; (ASA), acetylsalicylic acid; (ADP), adenosine diphosphate; (TXA2), thromboxane A2; 
(DR), diabetic retinopathy; (VEGF), vascular endothelial growth factor; (JNK), c-Jun N-terminal kinases; 
(ROP), retinopathy of prematurity ; (CHI), cerebral hypoxic-ischemic; (EP4), prostaglandin E receptor 4; 
(AMD), age-related macular degeneration; (RPE), retinal pigment epithelium; (FSK), forskolin; (HSC), hepatic 
stellate cells; (α-SMA),α-smooth muscle actin; (HPC), hematopoietic progenitor cells; (IP), inositol phosphate; 
(iDC), immature dendritic cells; (TNF-α), tumor necrosis factor α; (IL-1β), pro-inflammatory cytokine 
interleukin-1 beta; (IFN--γ), interferon-γ; (IRI), ischemia-reperfusion injury. 
  
1. SUCCINATE RECEPTOR 1 STRUCTURE AND LIGANDS 
SUCNR1 was first spotted in a megacaryocytic cell line in 1995 and called "P2U2", a name coined for its 
homology with the purinergic receptor P2Y2, known as P2u at that time (Gonzalez et al., 2004). SUCNR1 gene 
was later re-discovered as GPR91 in 2001 on human chromosome 3q24-3q25 using an expressed sequence tag 
data mining strategy (Wittenberger et al., 2001). Of important note is the possibility of two open-reading frames 
(ORF) for SUCNR1, one giving a protein of 330 amino acids (AA) and the other one 334 AA. Wittenberger et al. 
noted that the 330-AA protein was more likely to be expressed given the Kozak sequence surrounding the 
second ATG (Wittenberger et al., 2001). In the present article we will use the AA numbering according to a 330-
AA protein, although the current databases sometimes report SUCNR1 as being 334-AA long. There is a high 
degree of homology between man and mouse (68%) with the exception of the C-terminal tail, which is 12 AA 
shorter in rodents (Ariza et al., 2012; Wittenberger et al., 2001). In humans, other genes have been found on the 
same locus and consist in a cluster of P2Y1, P2Y12, P2Y13, H963 (GPR171) and GPR87 (Abbracchio et al., 2006). 
In their seminal paper, Wittenberger et al. speculated that all these receptors originated from a common ancestor, 
presumably a nucleotide receptor (Wittenberger et al., 2001). Several comprehensive reviews have been 
published on the receptor or succinate role in metabolic/oxidative stress conditions (Ariza et al., 2012; Peti-
Peterdi et al., 2013). The present work, in addition to discussing the most recent developments, considers 
extensively the mechanisms linking SUCNR1-activated signaling pathways and all (patho)physiological states 
where the receptor might play a role. 
SUCNR1 belongs to G protein-coupled receptors (GPCRs) family. In the human genome, it is the largest group 
of proteins involved in signal transduction across biological membranes (Fredriksson et al., 2003). GPCRs are 
currently the direct or indirect target for ~60% of marketed drugs and thus the most successful receptor family 
for treating human diseases (Davenport et al., 2013). GPCRs are classified into different families according to 
sequence homology and to their various types of ligands. Rhodopsin-like or class A GPCRs can be sub-divided 
in four groups: α, β, γ and δ. SUCNRl belongs to the latter (Fredriksson et al., 2003) and possesses a number of 
highly conserved residues and short-sequence motifs (Venkatakrishnan et al., 2013; Wittenberger et al., 2001). 
SUCNRl was initially viewed as a purinergic receptor due to its high sequence homology with P2Y receptors 
(29% with P2Y1 (Wittenberger et al., 2001)) and predicted to bind purinergic ligands (Fredriksson et al., 2003; 
Joost & Methner, 2002; Wittenberger et al., 2002). However, it has been paired by He et al. with a molecule not 
even remotely similar to purines: succinate (He et al., 2004). 
Receptors responding to purines and derivatives are classified between ionic channels P2X and metabotropic 
receptors (GPCRs) P2Y In 2006, the P2Y family was divided between P2Y1-like receptors and P2Y12-like 
receptors based on three criteria (Abbracchio et al., 2006). First, phylogenetic similarity, second the presence of 
AA motifs proposed to be important for ligand binding, and, third, primary G protein coupling. Regarding the 
second criterion, SUCNRl has some interesting similarities with P2Yi-like receptors in the TM6 (see below) 
such as the H6.52XXR/K6.55 and a slightly modified Q/KXXR (SUCNR1 has IVTR7.38) motifs (superscript 
indicates residue numbering using Ballesteros-Weinstein nomenclature (Ballesteros & Weinstein, 1995)). They 
might be important for agonist activity. For the third criterion, SUCNRl, just like P2Y12, 13, 14 receptors, almost 
exclusively couples to Gi/0 (see below) in contrast with P2Y1-like receptors that preferentially activate Gq 
signaling and induce calcium release (Abbracchio et al., 2006). Therefore, with regard to purinergic receptor 
classification, SUCNR1 cannot be related to either class, although it has striking similarities with this family. 
A better understanding of SUCNR1 structure will be a key step towards development of potent small-molecules 
modulators. Little information is currently available concerning the receptor tridimensional structure. Recently, 
many crystallographic data for class A GPCRs bound to different ligands, in different crystal forms or using 
different approaches to receptor stabilization and crystallization have been disclosed (a complete listing is 
outside the scope of this article but readers may find complete information in recent reviews (Katritch et al., 
2013; Zhang et al., 2015)). Although SUCNR1 has not been crystallized yet, the information on its structure can 
be hypothesized by comparison with closely related proteins. Two representative purinergic receptors (P2Y1 and 
P2Y12) have been crystallized recently (Zhang et al., 2015; Zhang J. et al., 2014; Zhang K. et al., 2014) and some 
careful inferences can be made on SUCNR1 structure. 
1.1. Extracellular domains 
SUCNR1 shares with GPCRs the general extracellular structure where transmembrane domains are connected by 
three hydrophilic extracellular loops (ECLs). A disulfide bond highly conserved among GPCRs links the top of 
the TM3 (at the end of ECL1) to the middle of ECL2 and is present in many GPCRs. The presence of two 
conserved cysteines in ECL2 (C168) and top of TM3 (C913.25) suggests that SUCNR1 possesses this canonical 
disulfide bridge (Fig. 1). 
A second conserved disulfide bridge is often observed between the N-terminus of the receptors and the top of 
TM7 (or at the end of ECL3). It stabilizes the extracellular structures and forms a pseudo-loop that has recently 
  
been defined as "ECL4" (Szpakowska et al., 2014). This feature is present in both P2Y12 and P2Y1 crystal 
structures (Zhang et al., 2015; Zhang J. et al., 2014). It is tempting to speculate that SUCNR1 has a similar 
architecture since it has two cysteines positioned at topologically similar positions (C7 and C2647.26). Resolution 
of SUCNR1 crystal structure is expected to confirm the presence of the disulfide bonds and mutations of these 
residues should show if the bridges are critical for interactions with ligands. 
SUCNR1 has two N-glycosylation sites, at N8 and N168 in the N-terminus and in the second extracellular loop, 
respectively (Robben et al., 2009; Wittenberger et al., 2001). However the precise role of this post-translational 
modification remains unknown. These post-translational modifications have been well characterized in some 
members of the P2Y family. For example, N-linked glycosylation of P2Y12 receptors is essential for signal 
transduction (Zhong et al., 2004). In SUCNR1, there is also one phosphorylation site that might be important for 
the receptor internalization, i.e., S326 in the C-terminus (Fig. 1) (Wittenberger et al., 2001). 
1.2. Transmembrane domains and binding pocket 
SUCNR1 shares the classical features of class A receptors together with some typical characteristics of 
purinergic receptors. 
1.2.1. TM1-TM2 
N1.50 residue in TM1, together with the TM2 L2.46XXXD2.50, are implicated in interhelical hydrogen bonding 
(Venkatakrishnan et al., 2013; Wittenberger et al., 2001). 
1.2.2. TM3 
The conserved E/DR3.50Y motif plays an important role in controlling GPCR activation (Audet & Bouvier, 2012; 
Rovati et al., 2007). Current paradigm proposes that R3.50 participates in an "ionic lock" with a negatively 
charged glutamate (E6.32) in TM6. Studies have shown that disruption of this interaction leads to TM6 movement 
away from the TM bundle to facilitate interaction with G protein, suggesting a common conserved mechanism 
for receptor activation induced by ligand binding (Audet & Bouvier, 2012). Simultaneously, the Y7.53 of the 
conserved NP7.50XXY motif moves inside the bundle, blocking TM6 in an open conformation (Audet & Bouvier, 
2012). 
However this "ionic lock" is not formed in all GPCR structures co-crystallized with an antagonist. Like P2Y12, 
SUCNR1 bears a V6.42 that may exclude the formation of polar interactions between TM6 and the DRY motif. In 
the case of P2Y12 the authors suggested that, in accordance with observations of high levels of basal activity, the 
absence of the "ionic lock" could render it more sensitive to activation (Zhang J. et al., 2014). Alternative 
mechanisms may also exist because P2Y1 shows a HRY motif where H3.49 repels R3.50. This configuration leads 
to the stabilization of the C-terminus via hydrogen bond between R3.50 and A7.55 (Robben et al., 2009; Zhang et 
al., 2015). 
 
Fig. 1. Snake plot of SUCNR1. Blue: AA conserved within rhodopsin family; red : putative disulfide bridge; 
green: V6.42 may exclude the formation of an ionic lock between E6.32 and the DRY motif. ; yellow : potential 






SUCNR1 possesses the conserved W4.50 and a TM5 that may be bulged and bent at a highly conserved P5.50 
called proline kink (Audet & Bouvier, 2012). This feature is present in P2Y1 and distinct from P2Y12 (bearing N 
instead of P at position 5.50), P2Y13 and P2Y14 (V5.50). In P2Y12, it results into a TM5 with straight conformation 
and tilted orientation (Zhang J. et al., 2014; Zhang K. et al., 2014). SUCNR1 shows a FTP motif instead of the 
conserved WXP6.50 (Fig. 1). The replacement of tryptophan (W) by phenylalanine (F) seems to be a common 
feature in the δ group of rhodopsin family and may be involved in ligand binding (Zhang J. et al., 2014; Zhang 
K. et al., 2014). 
1.2.4. Binding pocket 
Site-directed mutagenesis showed the importance of several positively charged AA for succinate binding 
(R993.29, R2817.39, R2526.55 and H1033.33) (He et al., 2004). R7.39 and R6.55 are topologically shared with 
crystallized P2Y receptors where they seem to neutralize the phosphate negative charges of nucleotides (Zhang 
et al., 2015; Zhang et al., 2014a). A similar mechanism can be hypothesized for the carboxylate negative charges 
of succinate (Gonzalez et al., 2004; He et al., 2004). In contradiction with a shared mechanism for activation, the 
mutation of the highly conserved H6.52 that contributes to ligand recognition in P2Y1, P2Y2 and P2Y12 receptors 
does not abolish the interaction between SUCNR1 and succinate whereas a mutant of H3.33 does (Fig. 1) (He et 
al., 2004). 
1.3. Ligands 
Initially, succinate was detected in pig kidney extracts with [Ca2+]i transients measured on Chinese hamster ovary 
(CHO) cells heterologously transfected with SUCNR1 (He et al., 2004). In mouse, succinate intravenous 
infusion induces an increase in blood pressure (He et al., 2004). This effect is abolished in SUCNR1-deficient 
animals, although angiotensin II induced hypertension was similar in both genotypes (He et al., 2004). Succinate 
response seems to be highly specific because 800 pharmacologically active compounds as well as 200 carboxylic 
acids and structurally related analogues, including other citric acid cycle intermediates, were not able to fully 
activate the receptor (He et al., 2004). Only maleate and methylmalonate were able to induce a response with 5- 
  
to 10-fold lower potency compared to succinate (He et al., 2004). The partial agonist nature of maleate on 
SUCNR1 was independently confirmed recently (Gilissen et al., 2015). 
In 2011 Bhuniya et al. reported a screening hit with antagonist profile following high-throughput screening. This 
hit compound was reported as able to inhibit succinate mediated [Ca2+]i mobilization (IC50 = 0.8 µM) in CHO-
K1 cells overexpressing human SUCNR1. A structure-activity relationships study provided potent and selective 
(with respect to GPR99) antagonists with IC50 in the nanomolar range. 2c and 4c antagonists (Fig. 2) were 
demonstrated to inhibit succinate-induced blood pressure in rat (Bhuniya et al., 2011). Recently, this family of 
compounds gave rise to (99 m)Tc and (18)F radiotracers that may be useful for competition or labeling studies 
(Klenc et al., 2015). 
Interestingly, these antagonists showed no obvious structural relationship to succinate and no negative charges at 
physiological pH. The binding site for these compounds remains elusive because no competitive binding with 
succinate was performed. Given the absence of negative charges, it is tempting to speculate that the compounds 
might actually bind to a remote site compared to succinate and act as allosteric antagonists. These modulators 
represent reliable starting points for the validation of the receptor as drug target, but require deeper 
pharmacological characterization. 
 
Fig. 2. Known SUCNR1 ligands. Succinate and maleate are the active species at physiological pH. 
 
 
2. SUCCINATE RECEPTOR 1 SIGNALING PATHWAYS 
GPCR activation induces a conformational rearrangement that promotes the recruitment of heterotrimeric G 
proteins and activates its dissociation into α-subunit and a βγ dimer. These subunits are able to modulate the 
activity of effectors and mediate cellular responses. There are four main families of G proteins which differ in 
the signaling pathways they couple to: Gi/o and Gs regulate cyclic adenosine monophosphate (cAMP) through 
adenylate cyclase (AC) modulation, Gq/11 induces [Ca2+]i release from intracellular stores and G12/13 is involved 
in migration, growth and cell division (Wettschureck & Offermanns, 2005). Many GPCRs are desensitized and 
internalized upon activation. For most of them G protein-coupled receptor kinases (GRKs) phosphorylate the 
receptors at intracellular sites. The phosphorylated C-tail of an activated receptor promotes the binding of 
arrestins (Lefkowitz & Shenoy, 2005). These adapter proteins bring the receptors to clathrin-coated pits and may 
mediate further signaling. However, there are many exceptions to this central paradigm because several GPCRs 
do not require arrestins to get internalized. Many examples have been described such as the serotonin receptor 5-
HT2A (Gray et al., 2001), protease-activated receptor PAR1 (Paing et al., 2002), prostacyclin receptor IP (Smyth 
et al., 2000), leukotriene B4 receptor BLT1 (Chen et al., 2004), formyl-peptide receptor FPR (Vines et al., 2003) 
or muscarinic receptor M2 (Vogler et al., 1999). 
SUCNR1 was originally described as being coupled to both Gi and Gq proteins in human embryonic kidney 
(HEK293) cells (He et al., 2004). The initial results were later confirmed by Robben et al., in polarized Madin 
Darby Canine Kidney (MDCK) cells (Robben et al., 2009). Several authors repeatedly confirmed Gi activation 
by demonstrating a decrease of cAMP levels upon succinate binding to SUCNR1 (Fig. 3), in both heterologous 
  
and native systems (Gilissen et al., 2015; Gnana-Prakasam et al., 2011 ; Hakak et al., 2009; Hogberg et al., 2011 
; Sundström et al., 2013). However, the view of SUCNR1 being coupled to Gq has been challenged and it was 
proposed by several authors that the observed [Ca2+]i mobilization was a consequence of PLC-β activation by the 
βγ dimer (Fig. 3) (Gilissen et al., 2015; Sundström et al., 2013). The discrepancy between results may reflect 
distinct G protein partners among different cell types or artifacts induced by overexpression of the receptor. The 
existence of Gq coupling with SUCNR1 requires additional investigations, especially in native and 
physiologically relevant systems. 
Succinate binding to SUCNR1 triggers the activation of mitogen-activated pathway (MAP) kinases, especially 
extracellular signal-regulated kinases 1 and 2 (ERK1/2) in HEK293 cell line (Gilissen etal., 2015; He et al., 
2004), MDCK (Robben et al., 2009), immature dendritic cells (iDC) (Rubic et al., 2008), retinal ganglion 
neuronal cell line (RGC) (Hu et al., 2013), TF-1 (human erythroleukaemia cell line) and cardiomyocytes (Aguiar 
et al., 2010) (Fig. 3). Some results indicate that ERK activation is Gi-dependent and should probably be mediated 
through the dimer βγ (Gilissen et al., 2015; Hakak et al., 2009). SUCNR1 is internalized into vesicular structures 
upon succinate exposure in HEK293 cells (He et al., 2004). In contrast, Robben et al., showed that SUCNR1 is 
rapidly desensitized and re-sensitized but not internalized in polarized MDCK cells (Robben et al., 2009). 
Hogberg et al. also showed desensitization of SUCNR1 in platelets (Hogberg et al., 2011). The coupling of 
activated receptor to arrestins 2 and 3 is very weak (Gilissen et al., 2015; Southern et al., 2013). Therefore, it is 
likely that homologous desensitization and internalization occur by a mechanism that does not involve arrestins. 
However, these questions have never been addressed directly. 
3. IMPLICATION IN (PATHO)PHYSIOLOGY 
Succinate is a citric acid cycle intermediate that accumulates in mitochondria, cytosol and outside the cell in case 
of oxygen deprivation due to the imbalance between energy demand and oxygen supply (Feldkamp et al., 2004; 
Hébert, 2004; Peti-Peterdi et al., 2013; Toma et al., 2008). It activates SUCNR1 signaling pathways for the 
detection of local stress, including ischemia, hypoxia, toxicity, and hyperglycemia. The succinate-SUCNR1 
response affects cellular metabolism and pathophysiology of diseases in multiple organs (Table 1 and Fig. 3). 
3.1. Regulation of blood pressure 
The observation that succinate may impact cardiovascular functions in humans dates back to the 50s when 
succinate infusions were tested as a treatment of barbiturate intoxications (Zuckerbrod & Graef 1950). In 1976, 
succinate was shown to induce renin release in isolated rat glomeruli while evaluating its role as an energy 
substrate (Baumbach et al., 1976). The mechanism for this effect was partially elucidated via the identification of 
its membrane receptor. The roles of succinate in blood pressure regulation have been well documented in several 
in vivo and in vitro studies and are strongly linked to the renin-angiotensin system (RAS) activation in the 
kidney (He et al., 2004; Pluznick & Caplan, 2015; Sadagopan et al., 2007; Toma et al., 2008). In addition, 
SUCNR1 mRNA has been detected in different nephron segments such as proximal tubule, distal nephron (He et 
al., 2004), afferent arteriole, glomerulus (Robben et al., 2009; Toma et al., 2008) and the juxtaglomerular 
apparatus (JGA), the most important regulatory site of systemic blood pressure (He et al., 2004). SUCNR1 
protein is also expressed in cortical collecting duct (CD), inner medullary CD principal cell and in macula densa 
(MD) cells (Robben et al., 2009; Vargas et al., 2009). MD cells are known to control renal blood flow, 
glomerular filtration, and release of renin (Peti-Peterdi & Harris, 2010; Robben et al., 2009; Vargas et al., 2009). 
The current model remains largely elusive but states that succinate binding to SUCNR1 results in production and 
release of prostaglandins I2 and E2 together with NO, which are vasodilators and crucial paracrine mediators of 
renin release by the juxtaglomerular apparatus (Robben et al., 2009; Toma et al., 2008). The production of these 
mediators is thought to be the consequence of [Ca2+]i increase and ERK1/2 phosphorylation (Fig. 3). Since renin 
is a key component of the renal ability to increase blood pressure in the face of low blood volume (Pluznick, 
2013), it is tempting to speculate that succinate may be acting via SUCNR1 to support increases in blood volume 
(and therefore blood pressure). Contradictions in this model include the reported increase of [Ca2+]i in 
glomerular endothelial cell line (GENC) by succinate that usually results in an inhibition of renin release 
(Amaral et al., 2012; Toma et al., 2008). Also, Sucnr1-/- mice have normal baseline blood pressures, likely due to 
long-term blood pressure counter-regulatory mechanisms. 
The pathological activation of the RAS contributes to or occurs with several pathological states such as diabetes, 
obesity or hypertension. Succinate and its receptor might play a key role in these conditions and metabolic 





Fig. 3. Signaling pathways following succinate binding on its receptor. Dashed lines represent hypothetical links 
and/or discrepancies in the literature (see text for details). 
 
3.1.1. Hypertension 
Circulating levels of succinate are elevated in rodent models of hypertension, including the spontaneously 
hypertensive rats. This aspect of succinate pathophysiology has not been confirmed in man (Sadagopan et al., 
2007). However, this does not preclude a local signaling role of succinate, which may not be reflected by the 
circulating levels. Hence, as an indirect example of chronic hypertension, serum succinate levels are increased in 
patients suffering from cardiac hypertrophy (CH) (Aguiar et al., 2014). Activated SUCNR1 may indirectly 
contribute to CH by inducing hypertension but might also have a direct action because it is expressed at protein 
level in ventricular cardiomyocytes (in sarcolemmal membrane and T-tubules) (Aguiar et al., 2010; Aguiar et al., 
2014). In these cells, SUCNR1 activation triggers hypertrophic gene expression via ERK1/2 phosphorylation, 
increased expression of calcium/calmodulin-dependent protein kinase IIδ (CaMKIIδ) and the translocation of 
histone deacetylase 5 (HDAC5) into the cytoplasm (Aguiar et al., 2014). Moreover, it was shown in another 
study by the same group as for cardiomyocytes, SUCNR1 alters Ca2+ transient via AC and protein kinase A 
(PKA) activation that phosphorylate phospholamban (PLN) and ryanodine receptor 2 (RyR2), two well-known 
Ca2+ handling proteins (Aguiar et al., 2010). These results suggest a Gs-mediated effect. However, the data are 
difficult to interpret because the concentration of succinate used was very high (10 mM) and the direct 
interaction of the receptor with Gs was not demonstrated (Aguiar et al., 2010). 
Considering that right ventricular hypertrophy (RVH) has a close relationship with left ventricle hypertrophy 
(LVH) (Yang et al., 2014), SUCNR1 may also be involved in RVH caused by pulmonary pressure overload via 
phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)/ protein kinase B (Akt) signaling pathway (Yang et al., 
2014). Interestingly this pathway is known to be activated by Gi in cardiac myocytes and its inhibition to convert 
survival to apoptotic signaling (Zhu et al., 2001). 
 
  
Table 1. Signaling pathways of SUCNR1 in specific cell sub-types. 
Tissue Cellular sub-types Cell lines used in 
vitro 





Kidney Proximal tubule, distal 
nephron, JGA, afferent 
arteriole and glomerulus 
Kidney and macula 
densa cells (Vargas et 
al., 2009) 
p38 and ERK1/2 
phosphorylation, renin release 
via COX-2 and PGE2 (Vargas 
et al., 2009) 
Hypertension 
   
 
 Diabetic nephropathy 
 Macula densa   
 
Renal complications 
(Robben et al., 2009; 
Vargas et al., 2009) 
  MDCK (Robben et al., 
2009) 
Gq and Gi, ERK1/2 
phosphorylation 
PGE2 and PGI2 via AA 
(Vargas et al., 2009) 
Hypertension (Vargas 
et al., 2009) 
  GENC (Toma et al., 
2008) 
↑Ca2+ 
renin release via NO and PGE2 
(Toma et al., 2008) 
Hypertension 
Liver Hepatic stellate cells  ↑ α-SMA 
↑ transdifferentiation (Correa 
et al., 2007; 
Li et al., 2015) 
Hepatic fibrosis 
(Correa et al., 2007; Li 
et al., 2015) 
White 
adipose 
Adipocytes (Regard et 
al., 2008) 
 Gi (Regard et al., 2008) Inhibition of lipolysis 
(Regard et al., 2008) 
Retina  RGC-5 (Deen & 
Robben, 2011 ; 
ERK1/2 and JNK 
phosphorylation, 
Diabetic retinopathy 
 RPE and microglial cells 
(Favretet al.,2013) 
Sapiehaet al., 2008) ↑ VEGF/cell proliferation via 
COX-2 and PGE2 (Deen & 
Robben, 2011 ; Hu et al., 2015; 
Jianyan Hu, Wu, Li, Chen, & 
Wang, 2013 ; Sapieha et al., 
2008) 
(Huet al.,2013) 
Blindness caused by 
ROP 
Dry-form AMD 
(Favret et al., 2013 ) 
Brain Neurons and astrocytes 
(Hamel et al., 2014) 
RGC-5 and RPA ↑ VEGF via PGE2 and EP4 
(Hamel et al., 2014) 
Brain revascularization 
(Hamel et al., 2014) 
Heart Sarcolemmal membrane 
and 
 ↑ Ca2+ via PKA and AC 
activation, PLN and RyR2 
phosphorylation (Aguiar et al., 
2010) 
Cardiac hypertrophy 
(Carla J. Aguiaret 
al.,2010) 
 T-tubules of 
cardiomyocytes 
(Aguiaret al.,2010) 
 ERK1/2 phosphorylation, 
CaMKIIδ expression and the 
translocation of HDAC5 
(Aguiar et al., 2014) PKA 
activation (Aguiar et al., 2010) 




(Aguiar et al., 2014) 
Myocytes death 
(Aguiar et al., 
2010) 








Gi Stimulation of 
immunity, protection 
from apoptosis (Hakak 
et al., 2009) 
 (Hakak et al., 2009) TF-1 (Hakak et al., 
2009) 
↑ IP, ERK1/2 phosphorylation 
(Hakak et al., 2009) 
 
Blood Immature dendritic cells 
(iDC) 
iDCandU937 ↑Ca2+ Enhancement of 
immunity transplant 
rejection (Rubic et al., 
2008) 
 (Rubic et aL, 2008)  ERK1/2 phosphorylation ↑ 
TNF-α, IL-1β and cytokines 





 Platelet (Macaulay et al., 
2007) 
 ↓ cAMP and Src kinase 
activation via Gi PI3K 
activation, Akt 
phosphorylation via βγ P-
selectin and glycoprotein 
(GP)IIb-IIIa activation 
(Hogberg et al., 2011 ) Cross-
talk with other GPCRs (ADP, 
TXA2) (Spath et al., 2012) 
↓ platelet aggregation 
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3.1.2. Diabetes and obesity 
Succinate accumulates locally in diabetic mouse kidneys (Toma et al., 2008). The increased levels associated 
with this condition are compatible with SUCNR1 receptor activation. The resulting renin release by the 
juxtaglomerular apparatus is absent in SUCNR1-deficient mice (Toma et al., 2008). Therefore, SUCNR1 may 
contribute to diabetes-induced hypertension by increasing renin release in conditions of chronic hyperglycemia, 
when filtrated succinate exceeds the reabsorbed levels (Robben et al., 2009). Since the urinary increase in 
succinate is one- to twofold in diabetic mice, there is an interest in urinary succinate as a potential early 
biomarker for diabetic nephropathy (Toma et al., 2008). 
 
One major complication of diabetes is diabetic nephropathy, a condition characterized by damage to the 
capillaries of renal glomeruli. Although RAS activation may contribute to the progression of diabetic 
nephropathy, the mechanism of this pathology is incompletely understood (Van Buren & Toto, 2011). 
Interestingly, ERK1/2 phosphorylation observed in diabetic nephropathy could be explained by succinate-
activated SUCNR1 in the renal tubules of diabetic mice (Robben et al., 2009). Thus, SUCNR1 may contribute to 
the development of tubulo-interstitial fibrosis and could become a target to prevent diabetic nephropathy (Peti-
Peterdi & Harris, 2010). 
Furthermore, rodent models of metabolic diseases, including ob/ob mice, and db/db mice, are characterized by 
increased circulating succinate levels which are sufficient to trigger the activation of SUCNR1 (Sadagopan et al., 
2007). SUCNR1 is expressed at the surface of adipocytes of the white adipose tissue (WAT) and stimulation of 
G; by succinate in these cells inhibits lipolysis and prevents the release of free fatty acids (Fig. 3) (McCreath et 
al., 2015; Regard, Sato, & Coughlin, 2008). 
Deep metabolic studies have recently demonstrated that Sucnr1-/-mice have a modified weight gain and glucose 
homeostasis (McCreath et al., 2015). Mice fed with standard diet displayed a mild lean pheno-type. However, 
KO mice under high-fat diet showed a significant reduction in weight gain (between 4 and 12 weeks), although 
this effect was lost at later time (>16 weeks). In KO mice, the overall content of WAT was increased and 
concomitant with a hyperglycemic profile, characterized by a reduced insulin secretion. According to McCreath 
et al., these results point to a role for SUCNR1 in metabolism and metabolic disease in the context of obesity 
(McCreath et al., 2015). 
Collectively, these data highlight the putative role of SUCNR1 in metabolic syndrome (MS), a pathological state 
characterized by obesity, diabetes and hypertension. People suffering from MS are at increased risk of 
developing cardiovascular disease. 
3.2. Platelet physiology 
Succinate was identified as a platelet stimulant more than 30 years ago (Huang et al., 1984). The precise 
mechanism of this effect remains unknown, but has been rediscovered and investigated more recently (Hogberg 
et al., 2011; Macaulay et al., 2007; Spath, Hansen, Bokemeyer, & Langer, 2012). 
SUCNR1 is expressed in megakaryocytes at both protein and mRNA levels (Hakak et al., 2009; Macaulay et al., 
2007). SUCNR1 is expressed in hematopoietic progenitor cells (HPC) of the bone marrow. In vitro, succinate 
stimulates the proliferation of erythroid and megakaryocyte progenitor cells as well as erythroid-like cell lines 
such as TF-1 cells. The proliferative effect seems to be mediated through Gi pathway that leads to the activation 
of ERK1/2 and inositol phosphate (IP) increase. These pathways are relevant for HPC proliferation, 
differentiation, and survival (Hakak et al., 2009). SUCNR1 also stimulates blood cell development by increasing 
the levels of hemoglobin, platelets, and neutrophils in a mouse model of chemotherapy-induced 
myelosuppression (Hakak et al., 2009). 
  
In addition, SUCNR1 has been identified as one of the most highly expressed GPCRs in human platelets, at a 
level corresponding to the P2Y1 receptor, indicating a potential important role in platelet physiology (Amisten et 
al., 2008 ; Hogberg et al., 2011 ; Macaulay et al., 2007 ; Spath et al., 2012). 
In vitro, succinate-induced platelet stimulation is dependent on Gs activation leading to cAMP decrease (Hogberg 
et al., 2011). PI3Kβ activation and Akt phosphorylation are also observed, presumably via the dimer βγ 
(Hogberg et al., 2011). Succinate-induced aggregation triggers Src kinase activation (Hogberg et al., 2011), 
atypical pathway for Gi-coupled receptors in platelets (Nash et al., 2010). At high concentration, succinate 
activates the first procaspase (PAC-1) that recognizes activated glycoprotein IIb/IIIa and the degranulation 
marker P-selectin (Hogberg et al., 2011). 
Conversely, some authors did not observe succinate-induced platelet aggregation (Spath et al., 2012). Although 
succinate may have a co-stimulatory role in platelet aggregation, it can also inhibit the effects of platelet 
inhibitors. This complex response may contribute to the inter-individual variability frequently observed in 
platelet function testing but may also explain the non-responsiveness to anti-platelet agents in patients affected 
by MS (Spath et al., 2012). For instance, platelet aggregation induced by arachidonic acid (AA) is completely 
abolished by preincubation with acetylsalicylic acid (ASA) but succinate restores responsiveness of ASA-treated 
platelets. A similar phenomenon was observed with platelet preincubated with P2Y12 receptor antagonist and 
stimulated with adenosine diphosphate (ADP) (Spath et al., 2012). 
3.3. Retinal angiogenesis 
Succinate has been shown to play an important role in hypoxia-induced retinal neovascularization (Sapieha et al., 
2008). In a 2008 milestone study, Sapieha et al. demonstrated that, in case of oxygen deprivation, the activation 
of SUCNR1 at the surface of RGC triggered the release of pro-angiogenic factors such as VEGF and 
angiopoietins (Sapieha et al., 2008). Furthermore, it was established that SUCNR1 activation promoted retinal 
angiogenesis in both normal retina and ischemic proliferative retinopathies (Sapieha et al., 2008). These results 
in mice have been substantiated in humans, in whom high levels of succinate have been detected in the vitreous 
fluid of patients suffering from diabetic retinopathy (DR) (Matsumoto et al., 2012). This proliferative retinopathy 
consecutive to hyperglycemia has an elusive pathophysiology although it is the leading cause of blindness in 20- 
to 74-years-old adults (Nolan et al., 2011). SUCNR1 might constitute an innovative drug target for DR Other 
retinopathies such as retinopathy of prematurity might also benefit from SUCNR1 antagonists (Joyal etal., 2012; 
Rivera etal., 2011). 
Further investigations performed in RGC-5 cell line (a retinal ganglionic cell line) strengthened the link between 
SUCNR1 pathways and the pathogenesis of DR. Notably, it was shown that SUCNR1 down-regulation prevents 
high glucose-induced release of VEGF (Hu et al., 2013). From a mechanistic point of view, the contribution of 
the succinate receptor to VEGF release seems to be a consequence of MAPK(ERK1/2, c-Jun & p38) activation 
(Hu et al., 2013; Hu et al., 2015). The downstream events linking SUCNR1 activation to VEGF release involve 
probably COX-2 activation and synthesis of PGE2 (Hu et al., 2015; Li et al., 2014). However, the upstream 
events responsible for MAPK activation have not been addressed yet in this system. 
Besides RGC, SUCNR1 is also present in retinal pigment epithelium (RPE) (Favret et al., 2013; Gnana-
Prakasam et al., 2011). Accordingly, a role for the receptor present in these cells has been suggested in 
hemochromatosis. This disease is characterized by an iron accumulation due to an imbalance in its homeostasis. 
Clinically, the iron overload is translated by age-dependent damages to various important organs such as liver, 
pancreas or the heart (Beutler, 2006). Hemochromatosis may presumably also play a role in age-related macular 
degeneration (AMD) (Blasiak et al., 2009; Dunaief, 2006; Gnana-Prakasam et al., 2009) because excess in iron 
may cause oxidative stress in RPE. The link has been evidenced in vivo in some animal models (Gnana-
Prakasam et al., 2009). In line with this hypothesis, Gnana-Praskam et al. have identified a polarized SUCNR1 
expression at the apical surface of retinal endothelium (Gnana-Prakasam et al., 2011). Interestingly, the protein 
levels were upregulated in the presence of iron and SUCNR1 was partially linked to VEGF expression in RPE, 
although the mechanism was not elucidated. 
The most common form of AMD is called "wet" (or exudative) and is characterized by neo-vascularization. A 
link has been recently proposed between SUCNR1 and "dry" (or atrophic) AMD, the other (less frequent) form, 
characterized by extracellular deposits called drusen, but no neo-vascular proliferation. In this study, SUCNR1 
knockout mice showed signs of premature AMD-like lesions such as sub-retinal accumulation of oxidized-LDL, 
elevated sub-retinal microglia (due to an impaired migration) and thickening of Bruch's membrane. It is 
interesting to note that in humans, SUCNR1 sequence variants are associated with atrophic AMD. Altogether, 
these observations offer the perspective of slowing down the progression of dry-form AMD by blocking 
SUCNR1 (Favret etal., 2013). 
3.4. ischemia/reperfusion injury 
  
Ischemia/reperfusion injury (IRI) represents a worldwide public health issue of increasing incidence. IRI may 
virtually affect all organs and tissues, and is associated with a significant morbidity and mortality. Particularly, 
the duration of blood supply deprivation has been recognized as a critical factor in stroke, myocardial infarction 
or acute kidney injury, as well as in solid organ transplantation or cardiac surgery (Eltzschig & Collard, 2004; 
Erpicum et al., 2014; Lagny et al., 2015). IRI causes multiple cellular and tissular metabolic and architectural 
changes (Carden & Granger, 2000). Furthermore, the reperfusion of ischemic tissues induces both local and 
systemic inflammation (Rowart et al., 2015). Various GPCRs have been implicated in the cascade of IRI 
(Weekers et al., 2015; Yap & Lee, 2012). Interestingly, tissue succinate levels have been shown to increase 
during ischemic hypoxia (Goldberg et al., 1966; He et al., 2004), which may reflect oxidative stress or energy 
deprivation. More recently, it has been demonstrated that succinate was responsible for mitochondrial reactive 
oxygen species (ROS) generation, a typical feature of IRI (Chouchani et al., 2014). In case of renal IRI, it has 
been suggested that accumulation of succinate could contribute to stenosis-associated hypertension (He et al., 
2004; Pluznick, 2013). Thus, preventing succinate accumulation may represent innovative therapeutic targets to 
protect against IRI-associated damage, notably in kidney or following heart attack (Chouchani et al., 2014; 
O'Neill, 2014). The specific role of SUCNR1 has been investigated in some animal models of IRI. 
In the liver, although succinate levels significantly increase following ischemia, neither succinate nor glucose are 
able to increase hepatic perfusion pressure when infused into the portal vein (Correa et al., 2007). Interestingly, 
succinate does not inhibit the production of cAMP induced by forskolin neither increase Ca2+ in quiescent 
hepatic stellate cells (HSC), where SUCNR1 is present, both at the protein and mRNA level (Correa et al., 
2007). However succinate accelerates activation of ischemic HSC, through upregulation of α-smooth muscle 
actin (α-SMA), a marker of myofibroblastic trans-differentiation (Fig. 3). Stimulation of SUCNR1 probably 
potentiates the effects of growth factors and hormones, and by non-traditional signals such as matrix stiffness or 
oxidant stress that are known to induce stellate cell activation (Correa et al., 2007). Upon activation of HSC, the 
expression of SUCNR1 in these cells decreases rapidly, suggesting that SUCNR1 serves as an early detector of 
hepatic stress or damage. SUCNR1 signaling plays an enhancing role in HSC activation to restore damaged 
tissues in the ischemic liver, but may also contribute to the formation of fibrosis (Correa et al., 2007; Y.H. Li, 
Woo, Choi, & Cho, 2015). 
In contrast, high levels of succinate after cerebral 1R1 enhance brain vascularization and recovery by inducing 
expression of VEGF through SUCNR1, which is mainly expressed in neurons and astrocytes (Hamel et al., 
2014). In RGC and rat cerebral astrocyte neuronal cell line (RPA), SUCNR1 upregulates VEGF via PGE2 and 
prostaglandin E receptor 4 (EP4), already known to promote angiogenesis (Hamel et al., 2014). Since succinate 
only transiently accumulates in case of brain 1R1, long-acting agonists of SUCNR1 might potentiate the 
recovery process (Hamel et al., 2014). 
3.5. Immune system and inflammation 
In humans, SUCNR1 protein was identified at the surface of T (CD4+, CD8+) and B (CD19+) cells as well as 
monocytes (CD14+) (Macaulay et al., 2007). At the mRNA level, SUCNR1 was also detected in macrophages 
and iDC (Rubic et al., 2008). Accumulating evidence points to succinate as a prominent signal molecule in 
inflammation, through the stabilization of the hypoxia-inducible factor (HIF-α), induction of the pro-
inflammatory cytokine interleukin-1 beta (IL-1β) and generation of mitochondrial ROS (Chouchani et al., 2014; 
Mills & O'Neill, 2014; Tannahill et al., 2013). The elevation of succinate levels is described as a consequence of 
hypoxia at sites of inflammation, with a switch to glycolysis by macrophages driven by HIF-α (Mills & O'Neill, 
2014). The role of SUCNR1 in these processes remains unknown but its function has been investigated in some 
specific inflammatory and immune response processes such as dendritic cells activation. 
Dendritic cells are an important population of antigen-presenting cells implicated in the initiation of immune 
response. They derive from monocytes and become iDC in peripheral tissue. Once in contact with antigens and 
various pathogens' stimuli they secrete proinflammatory cytokines and undergo maturation to dendritic cells. 
They thus migrate to the lymph node where they can activate T cells. In vitro, SUCNR1 is present at the surface 
of iDC and can elicit direct stimulation by [Ca2+]i mobilization (Rubic et al., 2008). Succinate also directly 
triggers migration of dendritic cells and this effect may also be indirect, by facilitating leukocytes trafficking 
through blood flow acceleration (Rubic et al., 2008). In synergy with toll-like receptors (TLR3 and TLR7), 
succinate bound SUCNR1 potentiates the expression of tumor necrosis factor α (TNF-α) and IL-1β and 
potentiate cytokines production via ERKl/2 phosphorylation. Succinate can be seen as an endogenous "warning" 
signal, regulating cytokines expression by iDC during their migration to the lymph nodes (Rubic et al., 2008). Of 
important note, SUCNR1 may contribute to transplant rejection because skin allografts have a longer survival 
time in immunocompetent SUCNR1-!- mice (Rubic et al., 2008). 
4. CONCLUSION 
On the basis of the existing observations mostly acquired from in vitro and in vivo rodent models, SUCNR1 
  
represents a promising drug target in various common human diseases, like hypertension, diabetes and IRI. 
However, the current paucity of specific pharmacological tools delays its validation as a drug target. Up to now, 
no synthetic agonists and very few ligands have been described. More widely available tools should rapidly 
prompt further investigations on the putative binding pocket to facilitate the design of new modulators. Such 
ligands might be used to address more deeply the role of the receptor, particularly in systems more relevant to 
human physiology. 
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